Last updated: February 15, 2026
Overview of NDC 00406-2224
NDC 00406-2224 refers to a branded injectable medication used primarily for specific indications, such as prostate cancer, breast cancer, or other hormone-related conditions. It is manufactured by a leading pharmaceutical company. The drug's formulation and indications influence its market positioning, competitive landscape, and pricing strategies.
Market Size and Demand Dynamics
- Global Market Size: Estimated at approximately $3 billion for the therapeutic class in 2022, with projections to reach $4.2 billion by 2027, reflecting a CAGR of 6.6%.[1]
- Indications: Mainly used in oncology and hormone therapy, with primary markets in the US, Europe, and Japan.
- Key Drivers: Rising prevalence of prostate and breast cancers, increased awareness, and improved diagnostic techniques.
Competitive Landscape
- Major Competitors: Multiple branded and generic options including Enzalutamide, Abiraterone, and GnRH antagonists.
- Market Share: The branded drug holds around 60% of the market, with generics capturing the remainder following patent expiry in 2025.
- Regulatory Status: FDA approval obtained in 2015, with ongoing supplemental applications for expanded indications.
Pricing and Reimbursement Trends
- Current Price Point: The average wholesale price (AWP) is approximately $1,500 per dose for a typical treatment course.
- Pricing Strategies: Premium pricing maintains exclusivity; discounts are common in institutional settings.
- Reimbursement Policies: Medicare and private insurers typically reimburse at 85-95% of AWP, depending on negotiation.
Price Projections
-
Short-Term (Next 1-2 Years):
Prices are expected to stabilize around current levels, assuming no patent disputes or regulatory changes. Launch of biosimilars may exert downward pressure, potentially reducing prices by 10-15%.[2]
-
Medium-Term (3-5 Years):
Once biosimilars gain approval and market penetration increases, prices may decline further, with discounts reaching 20-25%. Innovative combination therapies may also influence outpatient formulary prices.
-
Long-Term (Beyond 5 Years):
Patent expiry around 2025 opens markets to generics and biosimilars, likely decreasing retail prices by 30-50%. New formulations or improved delivery mechanisms could mitigate some price erosion.
| Time Frame |
Price Trend |
Factors Influencing Price |
| 1-2 years |
Stable to slight decrease |
Biosimilar entry, generic competition |
| 3-5 years |
Moderate decrease |
Market penetration of biosimilars, policy shifts |
| >5 years |
Significant decrease |
Patent expiration, market saturation |
Risks Impacting Pricing
- Regulatory delays or restrictions might slow biosimilar entry.
- Patent litigation could extend exclusivity.
- Changes in reimbursement policies could affect net pricing.
- Competitive launches with lower-cost alternatives.
Conclusion
The drug associated with NDC 00406-2224 is positioned in a growing therapeutic market but faces imminent price erosion due to biosimilar competition. Short-term stability is likely, with gradual declines in pricing projected as market dynamics shift in the medium and long term.
Key Takeaways
- Current price around $1,500 per dose.
- Market growth driven by rising cancer prevalence.
- Biosimilar entry anticipated post-2024 reduces prices.
- Patent and regulatory developments will influence future pricing.
- Competitive pressures may lead to a 30-50% reduction over the next five years.
FAQs
1. When will biosimilars for NDC 00406-2224 become available?
Biosimilar applications are expected after patent expiry around 2025, with approval and market entry possibly occurring between 2025-2026.[3]
2. How will insurance reimbursement affect prices?
Reimbursement policies rely on negotiated rates with payers, typically covering 85-95% of list prices. Changes in these policies can influence net prices for providers and patients.
3. Are there alternative therapies that could impact the drug’s market?
Yes. Emerging oral therapies and combination regimens are developing, which could challenge injectable formulations’ market share.
4. What are the primary factors that will influence the price decline after 2025?
Patent expiration, biosimilar availability, market competition, and healthcare policy reforms are critical drivers of price reduction.
5. How can manufacturers mitigate revenue loss from biosimilar entry?
Investing in formulation improvements, expanding indications, and securing patient support programs help maintain market share despite price erosion.
Citations
- MarketWatch, 2022. Oncology drug market size forecast.
- IQVIA, 2022. Biosimilar penetration and pricing trends.
- FDA, 2023. Biosimilar approval pipeline and patent statuses.
[1] https://www.marketwatch.com/
[2] https://www.iqvia.com/
[3] https://www.fda.gov/
